drugset / Trial / NCT07168486
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells. Based on the preclinical characteristics of the LTG2950, CAR19.20.22 tri-specific CAR T-cells the Investigators have developed the following hypotheses to be tested in our phase Ia clinical trial. The Investigators hypothesize that these novel CAR T-cells will show: * good safety and tolerability * a high degree of efficacy * very good persistence * an acceptable level of exhaustion
Timeline
- Start
- 2024-10-28
- Primary completion
- 2027-07-01
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19.20.22 CAR T cells | Cell therapy | 0.75 cells/kg | Intravenous |
| Subject | CD19.20.22 CAR T cells | Cell therapy | 1 cells/kg | Intravenous |
| Subject | CD19.20.22 CAR T cells | Cell therapy | 2.5 cells/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |